Search Results - "SAAD, Everardo D"

Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better? by Saad, Everardo D, Zalcberg, John R, Péron, Julien, Coart, Elisabeth, Burzykowski, Tomasz, Buyse, Marc

“…Time-to-event end points are the most frequent primary end points in phase III oncology trials, both in the adjuvant and advanced settings. The evaluation of…”
Get full text

Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials by SAAD, Everardo D, KATZ, Artur, BUYSE, Marc

“…With the availability of several lines of therapy, overall survival (OS) has been progressively substituted by progression-free survival (PFS) and other…”
Get full text

Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward by Ciani, Oriana, PhD, Buyse, Marc, ScD, Drummond, Michael, PhD, Rasi, Guido, PhD, Saad, Everardo D., MD, Taylor, Rod S., PhD

“…Abstract The efficacy of medicines, medical devices, and other health technologies should be proved in trials that assess final patient-relevant outcomes such…”
Get full text

The case against censoring of progression-free survival in cancer clinical trials – A pandemic shutdown as an illustration by Jamoul, Corinne, Collette, Laurence, Coart, Elisabeth, D'Hollander, Koenraad, Burzykowski, Tomasz, Saad, Everardo D, Buyse, Marc

“…Abstract Background Missing data may lead to loss of statistical power and introduce bias in clinical trials. The Covid-19 pandemic has had a profound impact…”
Get full text

Central statistical monitoring of investigator-led clinical trials in oncology by Buyse, Marc, Trotta, Laura, Saad, Everardo D., Sakamoto, Junichi

“…Investigator-led clinical trials are pragmatic trials that aim to investigate the benefits and harms of treatments in routine clinical practice. These…”
Get full text

Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology by Goldberg, Richard M, Adams, Richard, Buyse, Marc, Eng, Cathy, Grothey, Axel, André, Thierry, Sobrero, Alberto F, Lichtman, Stuart M, Benson, Al B, Punt, Cornelis J A, Maughan, Tim, Burzykowski, Tomasz, Sommeijer, Dirkje, Saad, Everardo D, Shi, Qian, Coart, Elisabeth, Chibaudel, Benoist, Koopman, Miriam, Schmoll, Hans-Joachim, Yoshino, Takayuki, Taieb, Julien, Tebbutt, Niall C, Zalcberg, John, Tabernero, Josep, Van Cutsem, Eric, Matheson, Alastair, de Gramont, Aimery

“…Abstract Meta-analysis based on individual participant data (IPD) is a powerful methodology for synthesizing evidence by combining information drawn from…”
Get full text

Primary systemic chemotherapy of invasive lobular carcinoma of the breast by Katz, Artur, Dr, Saad, Everardo D, MD, Porter, Peggy, Prof, Pusztai, Lajos, MD

“…Summary Invasive lobular carcinoma is the second most frequent histological type of breast cancer and its incidence is increasing. It has unique clinical,…”
Get full text

Assessment of quality of life in advanced non-small-cell lung cancer: An overview of recent randomized trials by Saad, Everardo D, Adamowicz, Krzysztof, Katz, Artur, Jassem, Jacek

“…Abstract Background Health-related quality of life (HRQOL) parameters are often used as secondary endpoints in advanced non-small-cell lung cancer (NSCLC). We…”
Get full text

Literature Review and Practical Aspects on the Management of Oxaliplatin-Associated Toxicity by Hoff, Paulo M, Saad, Everardo D, Costa, Frederico, Coutinho, Anelisa K, Caponero, Ricardo, Prolla, Gabriel, Gansl, Rene C

“…Abstract Colorectal cancer is currently a public health priority because it is the second leading cause of cancer deaths in Western countries. Combination…”
Get full text

Brazilian Validation of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group (QLG) Computerised Adaptive Tests (CAT) Core by Marta, Gustavo Nader, de Souza, Tomás Y. T., Silva, Alice R. N. de Souza e, Pereira, Ana Paula A., Ferreira Neto, David R., Asso, Rie N., Degrande, Fabiana A. M., Nader-Marta, Guilherme, da Silva, Maurício F., Gadia, Rafael, Hanna, Samir A., Holzner, Bernhard, Saad, Everardo D., Petersen, Morten Aagaard

“…Background: This study aimed to validate the Brazilian version of EORTC CAT Core and compare the Brazilian results with those from the original European EORTC…”
Get full text

Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors by Michiels, Stefan, Saad, Everardo D., Buyse, Marc

“…Over the past 15 years, targeted therapy has revolutionized the systemic treatment of cancer. In parallel, there has been a growing debate on the choice of end…”
Get full text

Precision medicine needs randomized clinical trials by Saad, Everardo D., Paoletti, Xavier, Burzykowski, Tomasz, Buyse, Marc

“…Clinical trial design has dramatically evolved with the advent of precision medicine. As a result, expedited drug-approval decisions have been made on the…”
Get full text

Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy by Buyse, Marc, Saad, Everardo D, Burzykowski, Tomasz, Regan, Meredith M, Sweeney, Christopher S

“…Many candidate surrogate endpoints are currently assessed using a 2-level statistical approach, which consists in checking whether (1) the potential surrogate…”
Get full text

Overall Survival: Patient Outcome, Therapeutic Objective, Clinical Trial End Point, or Public Health Measure? by SAAD, Everardo D, BUYSE, Marc

Get full text

Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints by Saad, Everardo D, Buyse, Marc

“…Clinical-trial design, analysis, and interpretation entails the use of efficient and reliable endpoints. Statistical issues related to endpoints warrant…”
Get full text

Minimization in randomized clinical trials by Coart, Elisabeth, Bamps, Perrine, Quinaux, Emmanuel, Sturbois, Geneviève, Saad, Everardo D, Burzykowski, Tomasz, Buyse, Marc

“…In randomized trials, comparability of the treatment groups is ensured through allocation of treatments using a mechanism that involves some random element,…”
Get full text

Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints by Saad, Everardo D., Buyse, Marc

“…PURPOSE OF REVIEWClinical-trial design, analysis, and interpretation entails the use of efficient and reliable endpoints. Statistical issues related to…”
Get full text

Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis by Saad, Everardo D, Squifflet, Pierre, Burzykowski, Tomasz, Quinaux, Emmanuel, Delaloge, Suzette, Mavroudis, Dimitris, Perez, Edith, Piccart-Gebhart, Martine, Schneider, Bryan P, Slamon, Dennis, Wolmark, Norman, Buyse, Marc

“…Although frequently used as a primary endpoint, disease-free survival has not been validated as a surrogate for overall survival in early breast cancer. We…”
Get full text

Rethinking survival analysis: advancing beyond the hazard ratio? by Verbeeck, Johan, Saad, Everardo D

Get full text

Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer by Reinert, Tomas, Saad, Everardo D, Barrios, Carlos H, Bines, José

“…Hormone receptor-positive breast cancer is the most frequent breast cancer subtype. Endocrine therapy (ET) targeting the estrogen receptor (ER) pathway…”
Get full text